A Trial-Based Cost-Utility Analysis of Metastasis-Directed Therapy for Oligorecurrent Prostate Cancer

The optimal management of patients with oligorecurrent prostate cancer (PCa) is unknown. There is growing interest in metastasis-directed therapy (MDT) for this population. The objective was to assess cost-utility from a Belgian healthcare payer’s perspective of MDT and delayed androgen deprivation...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Cancers (Basel)
Auteurs principaux: De Bleser, Elise, Willems, Ruben, Decaestecker, Karel, Annemans, Lieven, De Bruycker, Aurélie, Fonteyne, Valérie, Lumen, Nicolaas, Ameye, Filip, Billiet, Ignace, Joniau, Steven, De Meerleer, Gert, Ost, Piet, Bultijnck, Renée
Format: Artigo
Langue:Inglês
Publié: MDPI 2020
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7016808/
https://ncbi.nlm.nih.gov/pubmed/31947974
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers12010132
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires